前列腺癌筛查指南变化后前列腺活检使用情况的地域差异
该研究利用2012至2014年Medicare数据,分析306个医院转诊区域内由每年完成11例及以上活检的医师实施的前列腺活检率变化。共识别395,993例活检,总体活检率从2012年每1000名男性11.68例降至2014年10.23例(-12.4%,p=0.11)。调整后平均活检率及随时间变化均存在显著地域差异,非洲裔美国人比例更高、有门诊手术中心可用及PSA检测更频繁的地区活检率更高。
要点
- 2012至2014年总体前列腺活检率从每1000名男性11.68例降至10.23例(-12.4%,p=0.11)。
- 调整后平均活检率中位数为每1000名男性9.08例(IQR 7.65-10.76),地域差异明显。
- 调整后活检率变化中位数为每1000名男性-1.49例(IQR -1.94至-1.22),各地变化幅度不同。
核心结论
- 自2012年前列腺特异抗原(PSA)筛查建议改变后,前列腺活检的实施率及其随时间的变化存在相当大的地域差异。
- 明确未测量的患者和医师层面因素的作用对于优化活检使用和减少活检危害至关重要。
研究设计与样本
- 利用2012年至2014年Medicare数据,识别由每年完成11例及以上活检的医师实施的前列腺活检。
- 计算306个医院转诊区域的年度活检率及2012年至2014年的变化,并进行多变量回归调整与年度活检率相关的因素。
- 估计调整后的前列腺活检率及随时间的变化。
主要发现
- 共识别395,993例活检,总体活检率从2012年每1000名男性11.68例降至2014年10.23例(-12.4%,p=0.11)。
- 非洲裔美国人比例更高的地区活检率更高(β=0.810,95%CI 0.235-1.384,p=0.006)。
- 有门诊手术中心可实施活检的地区活检率更高(β=0.892,95%CI 0.108-1.676,p=0.026)。
- PSA检测更频繁的地区活检率更高(β=2.462,95%CI 1.153-3.771,p<0.001)。
- 调整后平均活检率中位数为每1000名男性9.08例(IQR 7.65-10.76),调整后活检率变化中位数为每1000名男性-1.49例(IQR -1.94至-1.22)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate biopsy rates have paralleled decreasing prostate specific antigen screening rates since 2012. We hypothesized that biopsy rates and the change in rates since 2012 would vary considerably across hospital referral regions. MATERIALS AND METHODS: Using Medicare data from 2012 through 2014 we identified prostate biopsies performed by physicians who performed 11 or more biopsies annually. We calculated annual biopsy rates and changes in rates from 2012 to 2014 across 306 hospital referral regions. We performed multivariable regression adjusting for factors associated with annual biopsy rates (eg percent of patients older than 75 who were screened with prostate specific antigen and percent of the population that was African American). We also estimated adjusted prostate biopsy rates and changes with time across regions. RESULTS: We identified 395,993 biopsies. The overall rates decreased from 11.68 biopsies per 1,000 men in 2012 to 10.23 per 1,000 in 2014 (-12.4%, p = 0.11). Biopsy rates were higher in regions in which a greater percentage of the population was African American (β = 0.810, 95% CI 0.235-1.384, p = 0.006), ambulatory surgical centers were available where biopsy could be performed (β = 0.892, 95% CI 0.108-1.676, p = 0.026) and prostate specific antigen testing occurred more frequently (β = 2.462, 95% CI 1.153-3.771, p <0.001). There was marked geographic variation in the adjusted average biopsy rate (median adjusted rate 9.08 biopsies per 1,000 men, IQR 7.65-10.76) and in the change in biopsy rates with time (median adjusted rate change -1.49 biopsies per 1,000 men, IQR -1.94--1.22 per 1,000). CONCLUSIONS: Since 2012 there has been considerable geographic variation in the performance of prostate biopsies as well as changes with time after prostate specific antigen recommendations changed. Characterizing the role of unmeasured patient and physician level factors is crucial to optimize the use and minimize the harms of prostate biopsy.
引用
- Henry MA, Howard DH, Davies BJ, et al. Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines. J Urol. 2017. PMID: 28487099. doi:10.1016/j.juro.2017.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。